<DOC>
	<DOCNO>NCT00483769</DOCNO>
	<brief_summary>Glargine treatment improve clinical feature Cystic Fibrosis patient affect glucose derangement</brief_summary>
	<brief_title>One Year Glargine Treatment CFRD Children Adolescents</brief_title>
	<detailed_description>To evaluate effect glargine treatment BMI , lung function , acute pulmonary infection HbA1c cystic fibrosis ( CF ) patient different glucose derangement , eighty-seven patient screen glucose derangement fast hyperglycaemia abnormality oral glucose tolerance test . They classify basis “ gluco-score ” range 0-5 . Patients gluco-score &gt; 1 treated glargine . We report result first 20 patient complete 12 month treatment . BMI z-score , forced expiratory volume first second ( FEV1 ) , number acute lung infection previous year HbA1c study outcome .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Patients affect Cystic Fibrosis show glucose derangement . Patients with/without Cystic Fibrosis without glucose derangement .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Cystis Fibrosis</keyword>
	<keyword>Glucose intolerance</keyword>
	<keyword>Glargine</keyword>
	<keyword>FEV1 %</keyword>
</DOC>